Monoferric (Ferric Derisomaltose) Dosing Interval
Monoferric is typically administered as a single total dose infusion (TDI) of 1000 mg, with repeat dosing guided by laboratory reassessment at 4-8 weeks, not by a fixed weekly interval. 1, 2
Initial Dosing Strategy
Monoferric is FDA-approved as the only IV iron formulation with a label for total dose infusion, allowing administration of up to 1000 mg or 20 mg/kg (not exceeding 1500 mg) as a single infusion. 1, 2
The formulation should be diluted in 100 mL normal saline and infused over 30 minutes with standard precautions for monitoring infusion reactions. 1
Unlike ferric carboxymaltose (FCM), which in the United States requires two 750 mg doses administered 1 week apart, Monoferric's advantage is single-dose administration for most patients. 1
Timing of Repeat Dosing
Laboratory evaluation should occur 4-8 weeks after the initial infusion to determine if additional iron is needed, rather than scheduling a second dose at a predetermined weekly interval. 1
Key Monitoring Parameters at 4-8 Weeks:
- Complete blood count (CBC) 1
- Ferritin (goal ≥50 ng/mL in absence of inflammation) 1
- Transferrin saturation (TSAT <20% indicates ongoing iron deficiency) 1
- Hemoglobin should increase by 1-2 g/dL within 4-8 weeks of therapy 1
Critical caveat: Iron parameters should not be evaluated within 4 weeks of a total dose infusion, as circulating iron interferes with assays and produces spurious results. 1
When Repeat Infusions Are Necessary
The need for additional Monoferric depends entirely on the underlying cause of iron deficiency: 1
Single Infusion Sufficient:
- If the cause of iron deficiency has been eliminated, one TDI should suffice. 1
Multiple Infusions Required:
- Ongoing blood loss: Heavy menstrual bleeding, angiodysplasia, hereditary hemorrhagic telangiectasia, inflammatory bowel disease 1
- Malabsorption conditions: Post-bariatric surgery, autoimmune gastritis, celiac disease 1
- The frequency of repeat dosing depends on the degree of blood loss or malabsorption, not a fixed schedule 1
Real-World Dosing Intervals from Clinical Data
In a Canadian retrospective cohort study of 35 patients with non-dialysis-dependent CKD and peritoneal dialysis patients receiving Monoferric: 3
- Median time between first and second doses was 19.1 weeks 3
- Median time between second and third doses was 6.6 weeks 3
- This demonstrates that repeat dosing intervals are highly variable and individualized based on laboratory response and ongoing losses 3
Advantages Over Other IV Iron Formulations
Monoferric offers superior convenience compared to formulations requiring fixed weekly intervals: 1
- Unlike FCM (which requires two doses 1 week apart in the US), Monoferric allows complete iron repletion in a single visit 1
- Monoferric does not cause the severe hypophosphatemia associated with FCM (47-75% incidence with FCM vs. <10% with other IV irons including Monoferric) 4
- This makes Monoferric preferable for patients requiring repeated iron therapy, as FCM-induced hypophosphatemia can persist up to 6 months and cause osteomalacia with repeated dosing 4
Clinical Outcomes Supporting Single-Dose Strategy
Monoferric was the first IV iron formulation to demonstrate statistically significant reduction in cardiovascular death in heart failure patients with iron deficiency, supporting the efficacy of its single-dose approach. 1, 5
In the IRONMAN trial, patients with heart failure and iron deficiency anemia showed improved quality of life and reduced cardiovascular events with Monoferric, particularly those with eGFR <45 mL/min/1.73 m². 6, 5